Table 2.

Posttransplantation clinical events and transplant outcomes of the study cohort

ParameterAll (n = 54)
Immunogenic posttransplantation complications  
aGVHD, n (%)  40 (74.1) 
>1 episode within 1 year after HSCT, n (%) 8 (14.8) 
Severe aGVHD, grade ≥3, n (%) 6 (11.1) 
cGVHD, n (%) 13 (24.1) 
>1 episode within 1 year after HSCT, n (%) 2 (3.7) 
Moderate-to-severe cGVHD, n (%) 9 (16.7) 
Infectious posttransplantation complications  
Chronic viral infection, n (%)  
CMV 13 (24) 
EBV 11 (20.4) 
HHV-6 6 (11.1) 
HHV-8 1 (1.9) 
HSV 3 (5.6) 
BKV 5 (9.3) 
Respiratory viral infections, n (%)  
Influenza 5 (9.3) 
SARS-CoV-2 16 (29.6) 
RSV 4 (7.4) 
Rhinovirus 5 (9.3) 
Bacterial infections, n (%) 26 (48.2) 
Transplantation outcomes, n (%)  
Disease relapse 11 (20.4) 
Overall survival at 1 year after HSCT 50 (92.6) 
ParameterAll (n = 54)
Immunogenic posttransplantation complications  
aGVHD, n (%)  40 (74.1) 
>1 episode within 1 year after HSCT, n (%) 8 (14.8) 
Severe aGVHD, grade ≥3, n (%) 6 (11.1) 
cGVHD, n (%) 13 (24.1) 
>1 episode within 1 year after HSCT, n (%) 2 (3.7) 
Moderate-to-severe cGVHD, n (%) 9 (16.7) 
Infectious posttransplantation complications  
Chronic viral infection, n (%)  
CMV 13 (24) 
EBV 11 (20.4) 
HHV-6 6 (11.1) 
HHV-8 1 (1.9) 
HSV 3 (5.6) 
BKV 5 (9.3) 
Respiratory viral infections, n (%)  
Influenza 5 (9.3) 
SARS-CoV-2 16 (29.6) 
RSV 4 (7.4) 
Rhinovirus 5 (9.3) 
Bacterial infections, n (%) 26 (48.2) 
Transplantation outcomes, n (%)  
Disease relapse 11 (20.4) 
Overall survival at 1 year after HSCT 50 (92.6) 

aGVHD, acute graft-versus-host disease; BKV, polyomavirus BK; cGVHD, chronic graft-versus-host disease; EBV, Epstein-Barr virus; HHV-6, human herpesvirus 6; HHV-8, human herpesvirus 8; HSV, herpes simplex virus; RSV, respiratory syncytial virus.

Classification of aGVHD grading according to the National Institutes of Health criteria in which aGVHD can occur beyond 3 months based on clinical manifestations.

Close Modal

or Create an Account

Close Modal
Close Modal